¼¼°èÀÇ À§½Äµµ¿ª·ùÁúȯ(GERD) ½ÃÀå º¸°í¼­(2025³â)
Gastroesophageal Reflux Disease (GERD) Global Market Report 2025
»óǰÄÚµå : 1686453
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,496,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,390,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,284,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À§½Äµµ¿ª·ùÁúȯ(GERD) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ¾ÈÁ¤µÈ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 2.7%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 59¾ï 4,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ ¼ºÀåÀº Àα¸ °í·ÉÈ­, ÇコÄɾî ÁöÃâ Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ ÃâÇö, ¼ÒÈ­°ü Áúȯ ½ºÅ©¸®´× ÇÁ·Î±×·¥ Áõ°¡, °¡½¿¾ÎÀÌ À¯º´·ü Áõ°¡, ÀÇ·á±â±â ¼ö¿ä Áõ°¡ µî¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áø´Ü Áøº¸, ¼ö¼ú Áøº¸, Ç¥Àû¿ä¹ý °³¹ß, ¿ø°Ý ÀÇ·á ¼­ºñ½º ä¿ë µîÀÌ ÀÖ½À´Ï´Ù.

¾ËÄÚ¿Ã ¼ÒºñÀÇ ³ôÀº ¹ß»ý·üÀº À§½Äµµ¿ª·ùÁúȯ(GERD) ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾ËÄÚ¿Ã ¼·Ãë´Â ¿¡Åº¿ÃÀ» Æ÷ÇÔÇÑ À½·áÀÇ ¼·Ã븦 ÀǹÌÇϸç, °úµµÇÏ°Ô ¼·ÃëÇÏ¸é ½Äµµ ¿îµ¿À» ³·Ãß°í ½Äµµ ¾Ð·Â ¼öÁØÀ» ÀúÇϽÃÄÑ GERD °³¹ß¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 7¿ù ¿µ±¹ ±â°üÀÎ ÇÏ¿ø µµ¼­°üÀº 2022³â ¿µ±¹ ¼ºÀÎÀÇ 56%°¡ Áö³­ 1ÁÖÀÏ µ¿¾È ¾ËÄÚ¿ÃÀ» ¼·ÃëÇß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ µ¥ÀÌÅͷκÎÅÍ À½ÁÖ ½À°üÀÇ ³²³à Â÷À̰¡ ¹àÇôÁ³°í, ÀÌ ±â°£¿¡ ¾ËÄÚ¿ÃÀ» ¼·ÃëÇÑ ÀûÀº ³²¼ºÀÌ 61%, ¿©¼ºÀÌ 51%¿´½À´Ï´Ù. ±× °á°ú, À½ÁÖ ½À°ü Áõ°¡°¡ GERD ½ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

À§½Äµµ¿ª·ùÁúȯ(GERD) ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â À¯·Â ±â¾÷Àº GERD¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ Ä¡·á ÀåÄ¡ÀÇ µµÀÔ¿¡ ÁÖ·ÂÇÏ¿© ½ÃÀå¿¡¼­ÀÇ ¸®´õ½Ê À¯Áö¸¦ ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¸é, ¹Ì±¹ÀÇ ÀÇ·á ±â¼ú ±â¾÷ Laborie Medical Technologies´Â 2023³â 4¿ù, À§½Äµµ¿ª·ùÁúȯ(GERD)ÀÇ Áø´Ü¿¡ ƯȭÇÑ ¹«¼± pH ĸ½¶Çü ¿ª·ù °Ë»ç Áø´Ü ½Ã½ºÅÛ alpHaONEÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ¼±ÁøÀûÀÎ ½Ã½ºÅÛÀº ÃÖ´ë 96½Ã°£ÀÇ Æ÷°ýÀûÀÎ ¸ð´ÏÅ͸µ µ¥ÀÌÅ͸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ Æí¸®ÇÑ È®´ë ¹öư ¹× ½Å·Ú¼º ³ôÀº ĸ½¶ °ø±Þ ½Ã½ºÅÛÀ» °®Ãá ÄÄÆÑÆ®ÇÏ°í »ç¿ëÇϱ⠽¬¿î µðÀÚÀÎÀ» ÀÚ¶ûÇÕ´Ï´Ù. °Ô´Ù°¡ ¹öÃß¾ó Áö½Ã ÇÁ·Î±×·¥À» °®Ãá Àü¿ë ¼ÒÇÁÆ®¿þ¾î ¾ÖÇø®ÄÉÀÌ¼Ç ¹× À¯Àú°¡ Áõ»ó ¹öưÀ» Ä¿½ºÅ͸¶ÀÌ¡ÇÒ ¼ö ÀÖ´Â ¿É¼Çµµ °®Ãß°í ÀÖ¾î ÀüüÀûÀÎ À¯Àú üÇèÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¢±ÙÀº GERD Ä¡·á ½ÃÀåÀÇ ÁøÈ­¿¡ Å« ¿µÇâÀ» ÁÖ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, Äڷγª, ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Gastroesophageal reflux disease (GERD) is a condition characterized by the regurgitation of stomach acid into the esophagus, leading to irritation and discomfort. Treating GERD involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary drug categories used in the treatment of gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, and minimally invasive procedures such as EndoCinch, Stretta, Asphyx, and Transoral Incisionless Fundoplication (TIF). Antacids, for instance, function by neutralizing stomach acid, thus increasing the stomach's pH level to alleviate symptoms. Additionally, these treatment approaches can be divided into invasive and minimally invasive procedures, offering options that cater to the unique needs of patients. These therapies are made available through various healthcare providers, including hospitals, homecare services, and specialty clinics.

The gastroesophageal reflux disease (GERD) market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease (GERD) market statistics, including gastroesophageal reflux disease (GERD) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (GERD) market share, detailed gastroesophageal reflux disease (GERD) market segments, market trends and opportunities and any further data you may need to thrive in the gastroesophageal reflux disease (GERD) industry. This gastroesophageal reflux disease (GERD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease (GERD) market size has grown marginally in recent years. It will grow from $5.25 billion in 2024 to $5.35 billion in 2025 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (GERD) market size is expected to see steady growth in the next few years. It will grow to $5.94 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services.

The high incidence of alcohol consumption is expected to drive the growth of the gastroesophageal reflux disease (GERD) market. Alcohol consumption refers to the ingestion of beverages containing ethanol, which, when consumed in excess, can contribute to the development of GERD by reducing esophageal motility and lowering the pressure levels in the esophagus. For example, in July 2024, the House of Commons Library, a UK-based institution, reported that in 2022, 56% of adults in England had consumed alcohol in the past week. This data revealed a gender difference in drinking habits, with 61% of men and 51% of women having consumed alcohol during this period. Consequently, the increasing prevalence of alcohol consumption is fueling the growth of the GERD market.

Prominent companies operating in the gastroesophageal reflux disease (GERD) market are dedicated to the introduction of innovative treatment devices for GERD, aimed at maintaining their market leadership. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, designed specifically for the diagnosis of gastroesophageal reflux disease (GERD). This advanced system is capable of providing up to 96 hours of comprehensive monitoring data. Notably, it boasts a compact and user-friendly design with conveniently enlarged buttons and a dependable capsule delivery system. Moreover, it features a dedicated software application equipped with a virtual instruction program and the option for users to customize symptom buttons, thereby enhancing the overall user experience. This innovative approach is significantly impacting the evolution of the GERD treatment market.

In October 2022, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in the production of gastroesophageal reflux disease medications, established a strategic partnership with HK Inno.N Corporation, a South Korea-based pharmaceutical company, in an arrangement involving an undisclosed sum. This collaboration is aimed at jointly developing and launching tegoprazan, a pioneering potassium-competitive acid blocker (P-CAB), within the US and Canada. Tegoprazan, already authorized and available in South Korea and China, holds significant promise as an innovative addition to Sebela Pharmaceuticals' gastroenterology product line, catering to individuals dealing with gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal reflux disease (GERD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Reflux Disease (GERD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease (gerd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gastroesophageal reflux disease (gerd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal reflux disease (gerd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Gastroesophageal Reflux Disease (GERD) Market Characteristics

3. Gastroesophageal Reflux Disease (GERD) Market Trends And Strategies

4. Gastroesophageal Reflux Disease (GERD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Gastroesophageal Reflux Disease (GERD) Growth Analysis And Strategic Analysis Framework

6. Gastroesophageal Reflux Disease (GERD) Market Segmentation

7. Gastroesophageal Reflux Disease (GERD) Market Regional And Country Analysis

8. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market

9. China Gastroesophageal Reflux Disease (GERD) Market

10. India Gastroesophageal Reflux Disease (GERD) Market

11. Japan Gastroesophageal Reflux Disease (GERD) Market

12. Australia Gastroesophageal Reflux Disease (GERD) Market

13. Indonesia Gastroesophageal Reflux Disease (GERD) Market

14. South Korea Gastroesophageal Reflux Disease (GERD) Market

15. Western Europe Gastroesophageal Reflux Disease (GERD) Market

16. UK Gastroesophageal Reflux Disease (GERD) Market

17. Germany Gastroesophageal Reflux Disease (GERD) Market

18. France Gastroesophageal Reflux Disease (GERD) Market

19. Italy Gastroesophageal Reflux Disease (GERD) Market

20. Spain Gastroesophageal Reflux Disease (GERD) Market

21. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market

22. Russia Gastroesophageal Reflux Disease (GERD) Market

23. North America Gastroesophageal Reflux Disease (GERD) Market

24. USA Gastroesophageal Reflux Disease (GERD) Market

25. Canada Gastroesophageal Reflux Disease (GERD) Market

26. South America Gastroesophageal Reflux Disease (GERD) Market

27. Brazil Gastroesophageal Reflux Disease (GERD) Market

28. Middle East Gastroesophageal Reflux Disease (GERD) Market

29. Africa Gastroesophageal Reflux Disease (GERD) Market

30. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape And Company Profiles

31. Gastroesophageal Reflux Disease (GERD) Market Other Major And Innovative Companies

32. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease (GERD) Market

34. Recent Developments In The Gastroesophageal Reflux Disease (GERD) Market

35. Gastroesophageal Reflux Disease (GERD) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â